The overall objective of this UO1 application is to provide support for Phase I trials of new anti-cancer agents and for the conduct of pharmacokinetic, pharmacodynamic and other laboratory correlative studies. These studies will be performed by the Harvard Phase I Oncology Group consisting of investigators at Dana-Farber Partners Cancer Care (DFPCC), Beth Israel Deaconess Medical Center (BIDMC) and Children's Hospital Medical Center. The scope of the program will include Phase I and laboratory studies of: 1) investigational new cytotoxic drugs; 2) angiogenesis inhibitors; 3) signal transduction/cell cycle inhibitors; 4) differentiating agents; and 5) anti-cancer vaccines. In addition to pharmacokinetic analyses, laboratory and imaging studies, depending on the agent, will focus on inhibition of angiogenesis, alterations in signal transduction pathways, regulation of specific gene expression, induction of differentiation and activation of anti-tumor immunity. Since the agents to be studied are in part unknown at this point, we have selected the following studies as examples of our capabilities: 1) Inhibition of tumor angiogenesis with the combination of angiostatin and endostatin; 2) inhibition of signal transduction pathways with flavopiridol to increase the effectiveness of gemcitabine; 3) development of the spicamycin analog KRN5500 as a differentiating agent; and 4) induction of anti-tumor immunity with recombinant vaccinia viruses expressing the MUC1 carcinoma-associated antigen and TRICOM (LFA-3, B7.1 and ICAM-1).
The specific aims are to conduct: 1) a Phase I, pharmacokinetic and pharmacodynamic trial of the combination of angiostatin and endostatin; 2) a Phase I, pharmacokinetic and pharmacodynamic trial of gemcitabine and a novel schedule of flavopiridol; 3) a Phase I, pharmacokinetic and pharmacodynamic trial of KRN5500; and 4) a Phase I trial of recombinant vaccinia viruses that express MUC1 and TRICOM (B7.1, ICAM-1 and LFA-3). ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA062490-14
Application #
7227010
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (O1))
Program Officer
Ivy, S Percy
Project Start
1994-03-02
Project End
2008-07-14
Budget Start
2007-02-01
Budget End
2008-07-14
Support Year
14
Fiscal Year
2007
Total Cost
$602,616
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
LoRusso, Patricia M; Li, Jing; Burger, Angelika et al. (2016) Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors. Clin Cancer Res 22:3227-37
Liu, Joyce F; Barry, William T; Birrer, Michael et al. (2014) Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 15:1207-14
Shibata, Stephen I; Chung, Vincent; Synold, Timothy W et al. (2013) Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res 19:3631-9
Abrams, Jeffrey S; Mooney, Margaret M; Zwiebel, James A et al. (2013) Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. J Natl Cancer Inst 105:954-9
Liu, Joyce F; Tolaney, Sara M; Birrer, Michael et al. (2013) A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer 49:2972-8
Lu-Emerson, Christine; Snuderl, Matija; Kirkpatrick, Nathaniel D et al. (2013) Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro Oncol 15:1079-87
Haigentz Jr, Missak; Kim, Mimi; Sarta, Catherine et al. (2012) Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. Oral Oncol 48:1281-8
Raut, Chandrajit P; Boucher, Yves; Duda, Dan G et al. (2012) Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948). PLoS One 7:e26331
Eichler, April F; Chung, Euiheon; Kodack, David P et al. (2011) The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol 8:344-56
Cleary, James M; Shapiro, Geoffrey I (2010) Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer. Curr Oncol Rep 12:87-94

Showing the most recent 10 out of 20 publications